0029 GMT - Healius's divestment of its Lumus Imaging unit makes sense but the Australian pathology provider needs to give further detail on where it will deploy the proceeds, Macquarie analysts say. They see the divestment improving the Australia-listed company's balance sheet position, but want to know how it will deploy surplus proceeds into productivity and profitability initiatives. The analysts tell clients in a note that they expect net proceeds of about A$800 million and for Healius to repay its existing debt facilities, thus reducing net interest costs. Macquarie cuts its target price 16% to A$1.35 and keeps a neutral rating on the stock, which is down 4.7% at A$1.2725. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
November 17, 2024 19:29 ET (00:29 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。